Literature DB >> 19863533

Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma.

Boris Böll, Peter Borchmann, Max S Topp, Mathias Hänel, Katrin S Reiners, Andreas Engert, Ralph Naumann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19863533     DOI： 10.1111/j.1365-2141.2009.07963.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  24 in total

1.  A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.

Authors:  Todd A Fehniger; Sarah Larson; Kathryn Trinkaus; Marilyn J Siegel; Amanda F Cashen; Kristie A Blum; Timothy S Fenske; David D Hurd; Andre Goy; Stephanie E Schneider; Catherine R Keppel; Nina D Wagner-Johnston; Kenneth R Carson; Nancy L Bartlett
Journal:  Blood       Date:  2011-09-21       Impact factor: 22.113

2.  Discriminant analysis involving serum cytokine levels and prediction of the response to therapy of patients with Hodgkin lymphoma.

Authors:  Maria Kowalska; Joanna Tajer; Magdalena Chechlinska; Malgorzata Fuksiewicz; Beata Kotowicz; Małgorzata Syczewska; Jan Walewski; Janina Kaminska
Journal:  Tumour Biol       Date:  2012-06-08

3.  Lenalidomide induced good clinical response in a patient with multiple relapsed and refractory Hodgkin's lymphoma.

Authors:  Inga Mandac; Slobodanka Ostojic Kolonic
Journal:  J Hematol Oncol       Date:  2010-05-28       Impact factor: 17.388

Review 4.  Advances in the treatment of Hodgkin lymphoma.

Authors:  Dennis A Eichenauer; Andreas Engert
Journal:  Int J Hematol       Date:  2012-10-11       Impact factor: 2.490

5.  Novel therapies for Hodgkin Lymphoma.

Authors:  John W Sweetenham
Journal:  Ther Adv Hematol       Date:  2010-02

Review 6.  Advances in the treatment of relapsed or refractory Hodgkin's lymphoma.

Authors:  Radhakrishnan Ramchandren
Journal:  Oncologist       Date:  2012-03-02

7.  Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphoma.

Authors:  Anna Colpo; Ephraim Hochberg; Yi-Bin Chen
Journal:  Oncologist       Date:  2011-12-30

Review 8.  Insights into the molecular roles of heparan sulfate proteoglycans (HSPGs-syndecans) in autocrine and paracrine growth factor signaling in the pathogenesis of Hodgkin's lymphoma.

Authors:  Rajendra Gharbaran
Journal:  Tumour Biol       Date:  2016-06-18

9.  A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma.

Authors:  Joseph J Maly; Beth A Christian; Xiaohua Zhu; Lai Wei; Jennifer L Sexton; Samantha M Jaglowski; Steven M Devine; Todd A Fehniger; Nina D Wagner-Johnston; Mitch A Phelps; Nancy L Bartlett; Kristie A Blum
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2017-05-22

10.  The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients.

Authors:  Evgeny Klyuchnikov; Ulrike Bacher; Nicolaus Kröger; Ilya Kazantsev; Tatjana Zabelina; Francis Ayuk; Axel Rolf Zander
Journal:  Adv Hematol       Date:  2010-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.